Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Potential safety, benefits, and influence of the placebo effect in microdosing psychedelic drugs: A systematic review
Genís Oña, José Carlos Bouso
Neuroscience & Biobehavioral Reviews (2020) Vol. 119, pp. 194-203
Closed Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review
Michiel van Elk, David B. Yaden
Neuroscience & Biobehavioral Reviews (2022) Vol. 140, pp. 104793-104793
Open Access | Times Cited: 110
Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study
Federico Cavanna, Stephanie Müller, Laura Alethia de la Fuente, et al.
Translational Psychiatry (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 78
The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955–2021) and recommendations for the field
Vince Polito, Paul Liknaitzky
Neuroscience & Biobehavioral Reviews (2022) Vol. 139, pp. 104706-104706
Open Access | Times Cited: 70
Could psychedelic drugs have a role in the treatment of schizophrenia? Rationale and strategy for safe implementation
Gilly Wolf, Sandeep Singh, Karin Blakolmer, et al.
Molecular Psychiatry (2022) Vol. 28, Iss. 1, pp. 44-58
Closed Access | Times Cited: 38
Microdosing Psychedelics: Current Evidence From Controlled Studies
Robin J. Murphy, Suresh Muthukumaraswamy, Harriet de Wit
Biological Psychiatry Cognitive Neuroscience and Neuroimaging (2024) Vol. 9, Iss. 5, pp. 500-511
Open Access | Times Cited: 11
Navigating Groundlessness: An interview study on dealing with ontological shock and existential distress following psychedelic experiences
Eirini K. Argyri, Jules Evans, David Luke, et al.
SSRN Electronic Journal (2024)
Closed Access | Times Cited: 8
Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers
Joseph M. Rootman, Pamela Kryskow, Kalin Harvey, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 52
Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls
Joseph M. Rootman, Maggie Kiraga, Pamela Kryskow, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 34
Toward Mapping Neurobehavioral Heterogeneity of Psychedelic Neurobiology in Humans
Flora Moujaes, Katrin H. Preller, Jie Lisa Ji, et al.
Biological Psychiatry (2022) Vol. 93, Iss. 12, pp. 1061-1070
Open Access | Times Cited: 31
Keeping the promise: a critique of the current state of microdosing research
Rotem Petranker, Thomas Anderson, Emily C. Fewster, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 6
Experimental Models to Study Skin Wound Healing with a Focus on Angiogenesis
Eberhard Grambow, Heiko Sorg, Christian G. G. Sorg, et al.
Medical Sciences (2021) Vol. 9, Iss. 3, pp. 55-55
Open Access | Times Cited: 37
Anti-Inflammatory Effects of Serotonin Receptor and Transient Receptor Potential Channel Ligands in Human Small Intestinal Epithelial Cells
Gregory Ian Robinson, Dongping Li, Bo Wang, et al.
Current Issues in Molecular Biology (2023) Vol. 45, Iss. 8, pp. 6743-6774
Open Access | Times Cited: 14
Serotonergic psychedelics as potential therapeutics for post-COVID-19 syndrome (or Long COVID): A comprehensive review
Zhen Xuen Brandon Low, Shin Jie Yong, Hayam A Alrasheed, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2025), pp. 111279-111279
Closed Access
Vermont Primary Care Provider Perspectives on Psychedelics — A Cross-Sectional Study
Josephine Yalovitser, jonah levine, Cole Zweber, et al.
Journal of Psychoactive Drugs (2025), pp. 1-7
Closed Access
Do undergraduates’ views of psychedelics relate to the context for psychedelic use?
Dan Petrovitch, Jason Van Allen, Sean M. Mitchell, et al.
Drug Science Policy and Law (2025) Vol. 11
Closed Access
Cross-Sectional Associations Between Lifetime Use of Psychedelic Drugs and Psychometric Measures During the COVID-19 Confinement: A Transcultural Study
Dóra Révész, Genís Oña, Giordano Novak Rossi, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 30
Psilocybin and eugenol prevent DSS-induced neuroinflammation in mice
Timur Zanikov, Marta Gerasymchuk, Gregory Ian Robinson, et al.
Biocatalysis and Agricultural Biotechnology (2024) Vol. 56, pp. 103033-103033
Closed Access | Times Cited: 4
State Cannabis and Psychedelic Legislation and Microdosing Interest in the US
Kevin H. Yang, Nora Satybaldiyeva, Matthew R. Allen, et al.
JAMA Health Forum (2024) Vol. 5, Iss. 6, pp. e241653-e241653
Open Access | Times Cited: 4
Psilocybin and Eugenol Reduce Inflammation in Human 3D EpiIntestinal Tissue
Gregory Ian Robinson, Dongping Li, Bo Wang, et al.
Life (2023) Vol. 13, Iss. 12, pp. 2345-2345
Open Access | Times Cited: 10
Set and setting in microdosing: an oft-overlooked principle
Ido Hartogsohn, Rotem Petranker
Psychopharmacology (2022) Vol. 239, Iss. 12, pp. 3771-3777
Closed Access | Times Cited: 15
Psilocybin mitigates the cognitive deficits observed in a rat model of Fragile X syndrome
Valeria Buzzelli, Emilia Carbone, Antonia Manduca, et al.
Psychopharmacology (2022) Vol. 240, Iss. 1, pp. 137-147
Closed Access | Times Cited: 15
Natural language signatures of psilocybin microdosing
Camila Sanz, Federico Cavanna, Stephanie Müller, et al.
Psychopharmacology (2022) Vol. 239, Iss. 9, pp. 2841-2852
Open Access | Times Cited: 14
“A sense of the bigger picture:” A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use
Meghan DellaCrosse, Mollie Pleet, Emma Morton, et al.
PLoS ONE (2022) Vol. 17, Iss. 12, pp. e0279073-e0279073
Open Access | Times Cited: 14
Chronic Treatment With Psilocybin Decreases Changes in Body Weight in a Rodent Model of Obesity
Joyce Y. Huang, Michelle Pham, William J. Panenka, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 13
Effects of psilocybin, the 5-HT2A receptor agonist TCB-2, and the 5-HT2A receptor antagonist M100907 on visual attention in male mice in the continuous performance test
Arya Rahbarnia, Zhaoxia Li, Paul Fletcher
Psychopharmacology (2023)
Closed Access | Times Cited: 7
Page 1 - Next Page

Scroll to top